Form 4: Kalaris Therapeutics Officer Sells Shares to Cover Tax Obligations

Brett Hagen, Chief Accounting Officer of Kalaris Therapeutics, sold 907 shares of common stock on March 26, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Summary

• On March 26, 2025, Brett R. Hagen, the Chief Accounting Officer of Kalaris Therapeutics, Inc., sold 907 shares of common stock.
• The sale was executed at a weighted average price of $8.9693 per share, with individual transactions ranging from $8.70 to $9.60.
• The sale was to cover tax withholding obligations related to the vesting of restricted stock units and was automatic, not discretionary.
• Following the transaction, Hagen directly owns 1,925 shares of Kalaris Therapeutics stock.
• Hagen has also granted Andrew Oxtoby a Limited Power of Attorney for Section 16 reporting obligations, effective March 4, 2025.

Sentiment

Score: 5

Explanation: The document reports a routine transaction (stock sale for tax obligations) and a standard administrative update (power of attorney). It doesn't indicate any particularly positive or negative sentiment.

Industry Context

Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among company executives.

Key Dates

Keywords

Kalaris Therapeutics, Brett Hagen, stock sale, Form 4, Section 16, restricted stock units, tax withholding, power of attorney, Andrew Oxtoby